1. Generics Bulletin
  2. >>Products
  3. >>Generics

Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude

Four Generic Icosapent Ethyl Products Have Only 40% Market Share

 
• By Dean Rudge

The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.

Amarin
Amarin are standing tall on Vascepa record • Source: Shutterstock

Amarin’s largest shareholder, Sarissa Capital, has continued its broadside at the company for “wasting” the value of Vascepa (icosapent ethyl) – in response to Amarin insisting that its current market share for the purified fish oil cardiovascular brand was “unprecedented for any drug after two years of generic competition.”

According to the originator’s latest data, Vascepa continues to hold a 60% share of all icosapent ethyl prescriptions written in the US, more than two years after Hikma debuted competition

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.